Risk of COVID-19 after natural infection or vaccination
Anne-Marie Rick(University of Pittsburgh), Priyantha N. Wijewardane, Ian Hirsch(AstraZeneca (United Kingdom)), Amber Grant, S Green, Yunda Huang(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa), Glenda Gray(South African Medical Research Council), Matthew B. Laurens(University of Maryland, Baltimore), Jennifer Winbigler, Ying Huang(Fred Hutch Cancer Center), Stephen R. Walsh(Beth Israel Deaconess Medical Center), Beatriz Grinsztejn(Fundação Oswaldo Cruz), Karen L. Kotloff(University of Maryland, Baltimore), Hana M. El Sahly(Baylor College of Medicine), Paul Goepfert(University of Maryland, Baltimore), Marshall Nash, James G. Kublin(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa), Elizabeth Parker, Terry D. Klein, Thomas Martin(University of California San Diego), William Smith(SUNY College of Environmental Science and Forestry), Terry L. Poling, Cynthia L. Gay(University of North Carolina at Chapel Hill), Stacy Slechta, Holly Janes(Fred Hutch Cancer Center), Kathleen M. Neuzil(Center for Global Development), Frank Struyf(Janssen (Belgium)), Steven Shinn, Rebone M. Maboa(University of Limpopo), Dean Follmann(National Institute of Allergy and Infectious Diseases), Richard Glover, Lawrence Corey(Fred Hutch Cancer Center), Chenchen Yu(Fred Hutch Cancer Center), Brett Leav(University of Maryland, Baltimore), Christina A. Rostad(Emory University), Lisa M. Dunkle(Merck & Co., Inc., Rahway, NJ, USA (United States)), Robyn Hartvickson, Peter B. Gilbert(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa), Lindsey R. Baden(Brigham and Women's Hospital), Carina A. Rodriguez(Icahn School of Medicine at Mount Sinai), Sikhongi Phungwayo, Troy Holdeman, Tracy Klein, Thomas Klein, Bruce G. Rankin, Jayasree Krishnankutty, Colleen Jacobsen, Richard Gibson(Wellcome Sanger Institute), Atoya Adams, Eric N. Miller
Cited by 14
Related Papers
Prevention of HIV-1 Infection with Early Antiretroviral Therapy
|New England Journal of Medicine|2011|7k
Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates
|New England Journal of Medicine|2020|2.7k
Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19
|New England Journal of Medicine|2021|2.6k
Antiretroviral Therapy for the Prevention of HIV-1 Transmission
|New England Journal of Medicine|2016|1.7k